Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 30;4(1):128–147. doi: 10.1038/s43018-022-00491-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 1 — a. Kaplan-Meier, log-rank test and Cox proportional hazards regression model methods were used to study the overall survival from breast cancer diagnosis (‘First Primary Receptor at diagnosis’ column of Supplementary Table 2) in HER2 positive (HER2+, n = 10 patients), Hormone receptor positive and HER2 negative (HR + /HER2-, n = 17 patients) and TNBC (triple-negative breast cancers, n = 19 patients). b. Kaplan-Meier, the log-rank test and Cox proportional hazards regression model to study the overall survival from metastatic breast cancer diagnosis (‘Metastasis original receptors’ column of Supplementary Table 2) in HER2 + (n = 9 patients), HR + /HER2- (n = 24 patients) and TNBC (n = 21 patients). In absence of HR/HER2 status in the metastatic relapse we used the data from the most recent biopsy. c-d. Frequency bar chart displaying the frequency of clinical subtype (c) and molecular subtype (d) in AURORA (n = 123 tumors) compared with TCGA (n = 1027 tumors). In the AURORA cohort, we assigned ER and HER2 clinical status to those samples that had missing clinical values using the mRNA surrogates. e-g. Boxplot displaying the risk of recurrence based on subtype (ROR-S) (e) and proliferation (ROR-P) (f) and Proliferation score from PAM50 predictor (g) comparing TCGA primary tumors (n = 1027 tumors) vs AURORA primary tumors (n = 44 tumors) vs AURORA metastatic tumors (n = 70 tumors). Statistically significant values are highlighted in red. Comparison between more than 2 groups was performed by ANOVA with post hoc Tukey’s test, one-sided (panels e, f, and g). Normal-like samples were removed from this analysis. Box-and-whisker plots from panels e, f, and g, display the median value on each bar, showing the lower and upper quartile range of the data (Q1 to Q3) and data outliers. The whiskers represent the lines from the minimum value to Q1 and Q3 to the maximum value. EBC, early breast cancer; MBC, metastatic breast cancer; confidence interval (CI). Statistically significant values are highlighted in red.